The global markets were up driven by vaccine hopes - Monday Review, November 23

By: Miguel A. Rodriguez

12:04, 24 November 2020

1606207946.jpg
The global stocks were higher amid positive data from AstraZeneca

The US

AstraZeneca's effect seems to linger over the markets. Moreover, the President-elect Joe Biden is looking to nominate a former Federal Reserve Chair as Treasury Secretary boosted the momentum. USA30 rose 1.13%, while USA500 went up 0.61%. TECH100 added 0.22%.

Gold settled at $1,835 per ounce after, during intraday trading, it reached a low of $1,828.25 – a level unseen since July 17.

Crude Oil settled up 1.9% at $43.25 per barrel.

The Dollar Index closed the day at 92.264.

 

Asia and Australia

The stocks traded mixedly at the beginning of the week, some focusing on the pharma companies' progress towards a viable COVID-19 vaccine. Others focused on the rising number of infections.

HongKong45 went down 0.14% as it is battling a new wave of COVID-19 infections.

Down under, Australia200 gained 0.53% as the country eased some COVID-19 restrictions.

 

Europe

AstraZeneca seems to be on everyone's lips, as it made Europe50 gain 0.5% - the most significant increase the benchmark had since February. Germany30 went up 1%, while France40 ended 0.8% higher. UK100 inched up 0.3%.

Brent Oil rose 1.5% to $45.75 per barrel.

EUR/USD settled at 1.1874 after it added 0.2%.

Sources: reuters.com, investing.com

Share this article

This information prepared by capex.com/za is not an offer or a solicitation for the purpose of purchase or sale of any financial products referred to herein or to enter into any legal relations, nor an advice or a recommendation with respect to such financial products.This information is prepared for general circulation. It does not regard to the specific investment objectives, financial situation, or the particular needs of any recipient.You should independently evaluate each financial product and consider the suitability of such a financial product, by taking into account your specific investment objectives, financial situation, or particular needs, and by consulting an independent financial adviser as needed, before dealing in any financial products mentioned in this document.This information may not be published, circulated, reproduced, or distributed in whole or in part to any other person without the Company’s prior written consent.
Past performance is not always indicative of likely or future performance. Any views or opinions presented are solely those of the author and do not necessarily represent those of capex.com/zaJME Financial Services (Pty) Ltd trading as CAPEX.COM/ZA acts as intermediary between the investor and Magnasale Trading Ltd, the counterparty to the contract for difference purchased by the Investor via CAPEX.COM/ZA, authorised & regulated by the Cyprus Securities and Exchange Commission with license number 264/15.  Magnasale Trading Ltd is the principal to the CFD purchased by investors.